Additional Information
Market: NYSE LSE
Sector: Pharmaceuticals
EPIC: GSK
Latest Price: 48.29  (-1.65% Descending)
52-week High: 56.66
52-week Low: 46.35
Market Cap: 19,717.50M
1 year chart
1 day chart
GlaxoSmithKline
www.gsk.com

GlaxoSmithKline supplies an estimated seven per cent of the world's pharmaceutical market and has six major disease areas – asthma, virus control, infections, mental health, diabetes and digestive conditions.

GlaxoSmithKline taps into Isis Pharmaceuticals antisense drug delivery platform

31st Mar 2010, 11:48 am by Ian Mclelland
GlaxoSmithKline taps into Isis Pharmaceuticals antisense drug delivery platform

 

A growing trend in the past decade for even the largest pharmaceutical companies is to regularly partner with other companies in an effort to maximise exposure to a varied range of potential new drug candidates while also sharing out the high costs of developing new therapies.


London and New York pharmaceutical giant GlaxoSmithKline (NYSE:GSK, LSE:GSK) (“Glaxo”) has been one of the leader in this area, continually seeking new partnerships while also regularly restricting its own operations in an attempt to maximise its drug development pipeline while keeping research and development costs in check.


This morning Glaxo announced a new strategic alliance with US listed Isis Pharmaceuticals (NASDAQ:ISIS)(“Isis”) to jointly develop new therapies using Isis’ antisense drug delivery platform. The alliance will focus on potential candidates for rare and serious disease, including conditions that cause blindness and infectious diseases.
Antisense therapies target proteins involved in disease processes through the RNA that is involved in building these proteins. Isis’ platform develops therapies that bind to messenger RNA (mRNA) and inhibit the production of disease-causing protein.


Under the terms of the agreement announced this morning Glaxo will pay Isis an upfront fee of US$35 million and up to US$20 million in milestones up to Phase 2 proof of concept (PoC) per program. The agreement covers up to six programs. At the PoC stage, Glaxo will have an option to license the compound and will fund all additional development and commercialization costs.   Isis will also receive license and milestone payments on any compound that reaches commercialization.

The total potential value of the milestone and license fees, based on Glaxo successfully developing one or more compounds from each program, is nearly US$1.5 billion. Isis will additionally receive up to double-digit royalties on sales from any product that is successfully commercialized.


“This alliance provides GSK with access to Isis' expertise in drug discovery and development of RNA-targeted therapeutics, with Isis retaining responsibility for the discovery and development of compounds to the alliance targets from inception to PoC,” Glaxo stated.


Isis Pharmaceuticals has already successfully commercialized the world's first antisense drug, and has 22 drugs in development.

No investment advice


Proactive Investors North America Inc, trades as "Proactiveinvestors USA & Canada".


You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.


You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.


From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.


You understand that we may be providing advertising and/or marketing services to companies mentioned on the site. A full list of companies that are paying for services from us, or our affiliated companies in the UK and Australia can be viewed here